Could a common nerve drug replace carpal tunnel surgery?
NCT ID NCT06294821
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether 4-aminopyridine, a drug already approved for other nerve conditions, can improve symptoms of carpal tunnel syndrome or delay the need for surgery. Researchers will give 160 adults either the drug or a placebo for 6 weeks and track symptom changes using hand function questionnaires. The goal is to see if this medication can be a non-surgical treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
4-aminopyridine
What this could lead to
If it works, this could offer a non-surgical option to relieve carpal tunnel symptoms and postpone or avoid the need for surgery.
What could go wrong
This is an early phase 2 trial with only 160 participants. The drug may not improve symptoms better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPRESSION NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact